Study Stopped
end-of-study visit not completed within the protocol timeframe
IDEntification of New Predisposition Genes in Differentiated THYroid Cancer
IDENTHY-K
1 other identifier
interventional
34
1 country
2
Brief Summary
The purpose of this research is to find new predisposition genes for differentiated thyroid cancer (DTC).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Feb 2022
Longer than P75 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 5, 2021
CompletedFirst Posted
Study publicly available on registry
August 20, 2021
CompletedStudy Start
First participant enrolled
February 23, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 13, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
January 13, 2026
CompletedJanuary 28, 2026
January 1, 2026
3.9 years
August 5, 2021
January 26, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Type and Number of genetic variants associated with or causing the development of differentiated thyroid cancer
To be achieved by a whole genome sequencing (WGS) approach in a familial analysis of patients with differentiated thyroid cancer. In addition, high-throughput genotyping of multiple individuals in each family will allow complementary detection of genomic regions that are shared only by affected subjects
within 2 years
Secondary Outcomes (2)
Number of phenotypes associated to genotypes of CDT
within 2 years
Analysis of birthplace/family origin information
within 2 years
Study Arms (1)
WGS
EXPERIMENTALat inclusion visit : \- Blood collection for whole Genome sequencing will be performed At final visit : the results of the WGS will be delivered to patients
Interventions
Eligibility Criteria
You may qualify if:
- Probant subjects
- Minor or adult subject
- Adult subject or legal guardian for minor subjects agreeing to sign the study consent and biospecimen consent
- Subject with differentiated thyroid cancer without an identified causative mutation in the BAP1 and DICER 1 predisposition genes
- Patient affiliated to a valid social security plan
- Relative subjects
- Adult subjects
- Subject agreeing to sign the study consent and the biocollection consent
- Subject with differentiated thyroid cancer or from a family with several cases of differentiated thyroid cancer without a causal mutation identified in the BAP1 and DICER 1 predisposition genes
- Patient affiliated to a social security plan
You may not qualify if:
- Subject refusing to participate
- Subjects with a causal mutation identified in the predisposition genes: BAP1 and DICER 1
- Subjects under guardianship, curatorship or safeguard of justice or not socially insured
- Subjects with another syndromic predisposition to thyroid cancer (Cowden, Werner, PAF)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Vendée Hospital
La Roche-sur-Yon, France
Nantes University Hospital
Nantes, 44093, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 5, 2021
First Posted
August 20, 2021
Study Start
February 23, 2022
Primary Completion
January 13, 2026
Study Completion
January 13, 2026
Last Updated
January 28, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share